“…A study by Santos et al [11] found significant involvement of genes SHANK3, NLGN3, NLGN4, NRXN1, MDGA2, FHIT, HTR2A, SHANK2, GRIA3, ZNF778, PRKCα, CDH15, DIAPH3, GCH1, GRM5, MARK1, SLC17A6, IMMP2L, BZRAP1, SYNGAP1, ANK3, MAP1A, GABRR2, LAMC3, LRRC7, LRRIQ3, CADPS1, NUFIP, SEMA3A, SNAP29, MBD2, GAD2, DGKH, PARD3, PIK3CG, RELN, NRCAM, LAMB1, WNT2, FOXP2, GRM8, UBE2H, A2BP1, ATP10A, CADPS2, CNTN4, CNTNAP2, DLGAP2, EGR2, EN2, GABRB3, MET, SLC4A10, DISC1, NPTX2, PCDH9, AUTS2 and RBFOX1 in patients with ASD. Attention should be paid to genetic mapping and accurate diagnosis of patients for better customized follow-up, both therapeutic and using drugs.…”